NextFin News - The Unified Patent Court (UPC) has delivered a stark warning to global innovators: in the high-stakes arena of European patent litigation, silence is not merely golden—it is a prerequisite for survival. A recent ruling by the court, which has sent shockwaves through the intellectual property community this March, established that trade secrets disclosed during proceedings without an explicit confidentiality order lose their protected status. The decision, involving medical device firm EOflow, has effectively fired a starting gun for a surge in protective filings as companies scramble to shield their proprietary data from the public record.
The crux of the matter lies in the UPC’s interpretation of "reasonable steps" to maintain secrecy. In the EOflow case, the court determined that the failure to proactively seek a confidentiality order before sensitive information was aired in court stripped that information of its trade secret status. This is a departure from the more forgiving practices seen in some national jurisdictions, where a degree of inherent confidentiality is often assumed during the discovery or evidentiary phases. By placing the burden of protection squarely on the shoulders of the litigant from the very outset, the UPC has transformed confidentiality from a standard courtesy into a tactical necessity.
Legal practitioners at firms such as Vondst and Biopatents are already reporting a shift in client behavior. The ruling creates a "use it or lose it" dynamic that is expected to flood the UPC with requests for Rule 262 orders, which restrict access to specific pleadings or evidence. For multinational corporations, particularly those in the pharmaceutical and tech sectors where the line between a patented invention and a trade secret is often blurred, the risk of accidental disclosure is now a top-tier litigation hazard. A single procedural oversight could theoretically hand a competitor the keys to a manufacturing process or a chemical formula that took decades to refine.
This procedural hardening comes at a time when trade secret litigation is already on a steep upward trajectory globally. Data from early 2026 indicates that U.S. federal courts have seen a 30% year-on-year rise in trade secret filings, driven by the maturation of the Defend Trade Secrets Act and the increasing complexity of AI-related misappropriation cases. The UPC’s latest stance ensures that Europe will not be a laggard in this trend. However, while the U.S. system has become more comfortable with complex damages models for stolen secrets, the UPC is focusing its initial energy on the gatekeeping of information itself.
The strategic implications are profound. Defendants may now use the threat of public disclosure as a lever in settlement negotiations, knowing that a plaintiff might prefer to drop a secondary claim rather than risk a public airing of sensitive data. Conversely, aggressive litigants may seek to "flood the zone" with confidentiality requests, potentially slowing down the court’s ambitious timelines. The UPC, designed to be a streamlined and efficient alternative to fragmented national litigation, now faces the administrative challenge of processing a mountain of protective motions alongside its core patent caseload.
As the court enters its third year of operation, the EOflow ruling serves as a reminder that the UPC is not merely a venue for patent disputes, but a powerful arbiter of broader corporate intelligence. Companies can no longer afford to treat confidentiality as an afterthought or a post-script to a filing. In the new European legal landscape, the protection of a trade secret begins the moment a lawyer picks up a pen, and for those who wait until the first hearing to ask for privacy, the treasure chest may already be open.
Explore more exclusive insights at nextfin.ai.
